AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
| 3.26 | |
| 3.21 | |
| - | |
| 3.28 | |
| 3.145 | |
| 2.65-7.85 | |
| 912 M | |
| 294 M | |
| 35 787 K | |
| -0.14 | |
| 0.387 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Are you a successful asset manager who has already amassed more than $1 billion in personal wealth? If not, there are probably a few things you can learn from the small list of folks who have. Luckil...
In this article, we will take a detailed look at Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks. For a quick overview of such stocks, read our article Billionair...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
